Radical cystectomy for BCG failure: Has the timing improved in recent years?

BJU International

Volumn 108, Issue 2, 2011, Pages 182-185

  Soloway, Mark S ^a   Hepps, David ^a   Katkoori, Devendar ^a   Ayyathurai, Rajinikanth ^a   Manoharan, Murugesan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bacille Calmette Gu rin; bladder cancer; cystectomy

Indexed keywords

BCG VACCINE;

AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYSTECTOMY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 79959293570     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09830.x     Document Type: Article

References (17)

1. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet 2009; 374: 239-49
2. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al,. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-75; discussion 475-7 (Pubitemid 43259554)
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
4. Braasch MR, Bohle A, O'Donnell MA,. Risk-adapted use of intravesical immunotherapy. Br J Urol 2008; 102: 1254-64
5. Martin FM, Kamat AM,. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 2009; 9: 815-20
6. Herr HW, Sogani PC,. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166: 1296-9 (Pubitemid 32862159)
7. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA,. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004; 45: 292-6 (Pubitemid 38221401)
8. Bochner BH,. Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urol Oncol 2009; 27: 329-31
9. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR,. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 62-7 (Pubitemid 27251595)
10. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE,. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96-100; discussion (Pubitemid 35461560)
11. Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS,. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology 2006; 67: 737-41
12. Herr HW,. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 1997; 80: 762-5 (Pubitemid 28316341)
13. Nieder AM, Brausi M, Lamm D, et al,. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66: 108-25 (Pubitemid 43049612)
14. Lamm DL, Blumenstein BA, Crissman JD, et al,. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9 (Pubitemid 30169376)
15. Herr HW,. Is maintenance bacillus Calmette-Guérin really necessary? Eur Urol 2008; 54: 971-3
16. Huguet J, Gaya JM, Sabate S, Palou J, Villavicencio H,. Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy. Actas Urol Esp 2010; 34: 63-70
17. Fernandez-Gomez J, Solsona E, Unda M, et al,. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1001